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DOI 10.1016/j.ccr.2011.07.008SUMMARYTumor hypoxia is associatedwith disease progression and treatment failure, but the hypoxia signalingmech-
anism isnot fully understood.Here,weshow thatKLHL20, aCullin3 (Cul3) substrate adaptor inducedbyHIF-1,
coordinates with the actions of CDK1/2 and Pin1 tomediate hypoxia-induced PML proteasomal degradation.
Furthermore, this PMLdestruction pathway participates in a feedbackmechanism tomaximizeHIF-1a induc-
tion, thereby potentiating multiple tumor hypoxia responses, including metabolic reprogramming, epithelial-
mesenchymal transition, migration, tumor growth, angiogenesis, and chemoresistance. In human prostate
cancer, overexpression of HIF-1a, KLHL20, and Pin1 correlates with PML down-regulation, and hyperactiva-
tion of the PML destruction pathway is associated with disease progression. Our study indicates that the
KLHL20-mediated PML degradation and HIF-1a autoregulation play key roles in tumor progression.INTRODUCTION
Hypoxia is an essential feature of the microenvironment of solid
tumors. A keymechanismmediating the adaptation of hypoxia is
the induction of hypoxia-inducible factor 1 (HIF-1). This tran-
scription factor regulates a large panel of genes that play crucialSignificance
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2010; Semenza, 2010). Accordingly, accumulation of HIF-1 in
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HIF-1 is therefore considered as an attractive target for pharma-
ceutical intervention in cancer therapy.
HIF-1 is a heterodimeric protein composed of a tightly regu-
lated a subunit and a constitutively expressed b subunit (Wang
et al., 1995). The a subunit is subject to ubiquitin-mediated
proteolysis through an O2-dependent pathway and is stabilized
under hypoxia (Maxwell et al., 1999). In addition to this pathway,
the level and/or activity of HIF-1a are also controlled by a
complex network of positive and negative feedback regulators
(Henze and Acker, 2010). This intricate HIF-1a regulatory system
allows tumor cells to flexibly adjust and adapt hypoxia responses
to the diverse and fluctuating oxygen concentrations within the
tumor microenvironment, thereby benefiting tumor progression.
However, the regulatory network of HIF-1a and its signaling
mechanism in cancer cells have not been completely character-
ized, and a better understanding of these aspects may be bene-
ficial for cancer therapy.
Besides hypoxia, HIF-1a protein level can be up-regulated
in cancer by loss of function of several tumor suppressors
(Semenza, 2010), including the promyelocytic leukemia (PML)
protein (Bernardi et al., 2006). The PML gene was identified at
the breakpoint of the t(15; 17) chromosome translocations of
acute promyelocytic leukemia, which results in the generation
of oncogenic PML-RARa fusion protein (de The´ et al., 1990;
de The´ et al., 1991; Melnick and Licht, 1999). The PML protein
is essential for the assembly of discrete subnuclear structures
called PML-nuclear bodies (PML-NBs) (Ishov et al., 1999) and
plays a critical role in multiple cellular processes that are altered
in cancer, such as proliferation, apoptosis, senescence, migra-
tion, and angiogenesis (Bernardi and Pandolfi, 2007; Reineke
et al., 2010; Salomoni et al., 2008; Salomoni and Pandolfi,
2002). In addition, PML loss sensitizes mice to tumorigenesis in-
duced by physical or chemical carcinogens (Wang et al., 1998)
and accelerates tumor onset in several mouse cancer models
(Scaglioni et al., 2006; Trotman et al., 2006). In accordance
with its tumor suppressive role, down-regulation of PML protein
is frequently observed in diverse types of human tumors and is
correlated with tumor progression. Because PML transcripts
do not display a corresponding decrease, it has been proposed
that PML protein is aberrantly degraded in tumors (Gurrieri et al.,
2004; Salomoni et al., 2008).
PML protein degradation can be triggered by several signaling
pathways. For instance, As2O3-induced PML sumoylation facili-
tates its ubiquitination by ubiquitin ligase RNF4, thereby inducing
PML degradation (Lallemand-Breitenbach et al., 2008; Tatham
et al., 2008). PML phosphorylation by CK2 results in its ubiquiti-
nation and degradation (Scaglioni et al., 2006). The peptidyl-
prolyl cis/trans isomerase Pin1 (Reineke et al., 2008) and ubiqui-
tin ligases Siah (Fanelli et al., 2004) and E6AP (Louria-Hayon
et al., 2009) also act on PML to trigger its degradation. Although
several signals and molecules promote PML ubiquitination and/
or degradation, their contribution to frequent PML down-regula-
tion in human tumors remains largely unexplored.
Many BTB domain-containing proteins serve as substrate
adaptors in Cullin 3 (Cul3)–based ubiquitin ligases (Pintard
et al., 2004). We previously identified that the BTB family protein
KLHL20 forms an E3 ligase complex with Cul3 and Roc1 and
a portion of KLHL20 exists in PML-NBs (Lee et al., 2010). Inthis study, we investigated how KLHL20 regulates the abun-
dance of PML and the impact of this regulation on tumor hypoxia
responses.
RESULTS
Hypoxia Induces PML Destabilization and KLHL20
Transcription Through HIF-1
Hypoxia is known to regulate the expression of a number of
genes responsible for tumor progression. We tested whether
hypoxic stress influences the expression of PML. Hypoxia treat-
ment of prostate cancer cell lines LNCaP and PC3 led to a time-
dependent reduction of PML protein (Figure 1A) but not PML
mRNA (see Figure S1A available online). Most, if not all, PML iso-
forms detected in these cell lines were affected by hypoxia. This
hypoxia-induced PML down-regulation was observed in several
other cancer cell lines, such as CWR22Rv1 (prostate), T47D
(breast), H630 (colon), HCT116 (colon), and H1299 (lung) (Fig-
ure S1B). Cycloheximide-chase experiment revealed that hyp-
oxia accelerated PML protein turnover (Figure 1B) by reducing
t1/2 from 6 hr to 1.6 hr. Furthermore, proteasome inhibitor
MG132 triggered a greater PML up-regulation in hypoxic than
normoxic cells (Figure 1C), supporting an involvement of the
26S proteasome. Protein degradation through proteasome
usually results from polyubiquitin modification. We therefore
examined PML ubiquitination level. Using LNCaP cells
expressing PML-I, the longest and most abundantly expressed
isoform of PML (Condemine et al., 2006), we found that PML-I
polyubiquitination level was greatly elevated by hypoxia, as
determined by reciprocal precipitation for either PML-I or ubiqui-
tin (Figure 1D; Figure S1C). These results indicate that hypoxia
induces PML polyubiquitination, which in turn triggers its pro-
teasomal-dependent degradation.
Recent studies indicated that PML SUMO-2/3 conjugation
promotes its ubiquitination by recruitment of the ubiquitin ligase
RNF4 (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008).
To investigate whether hypoxia-induced PML ubiquitination was
triggered by its sumoylation, we utilized a sumoylation-defective
mutant PML-I 3KR (Figure S1D). Surprisingly, under hypoxia
conditions, this mutant was ubiquitinated and degraded to
similar extents as compared with the wild-type protein (Fig-
ure 1D; Figures S1C and S1E), indicating the existence of
a sumoylation-independent mechanism.
Our recent study revealed that KLHL20 functions as
a substrate adaptor of Cul3-based ubiquitin ligase and that a
portion of KLHL20 is localized in PML-NBs (Lee et al., 2010). In
agreement with a previous report (Nacak et al., 2007), hypoxia
led to the up-regulation of KLHL20 mRNA (Figure S1F) and
protein (Figure 1A). Overexpression of HIF-1a(6ODD), a nonde-
gradable mutant of HIF-1a, similarly induced KLHL20 (Fig-
ure S1G). Importantly, in both conditions, the increase of
KLHL20 was correlated with a decrease of PML expression.
The expression of RNF4, however, was unchanged (Figure 1A;
Figure S1G). In the reciprocal experiment, HIF-1a depletion
blocked hypoxia-induced up-regulation of KLHL20 and down-
regulation of PML (Figure 1E), further demonstrating opposite
regulations of the two proteins. To determine the mechanism
by which HIF-1a regulates KLHL20, we identified two putative
hypoxia-responsive elements (HREs) in promoter and intron 1Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc. 215
Figure 1. Hypoxia Induces Opposite Regulations of PML and KLHL20 through HIF-1a
(A) The expression of endogenous PML, KLHL20, and RNF4 in PC3 and LNCaP cells treated with hypoxia for indicated period.
(B and C) Western blot analysis of PML level in LNCaP cells cultured in normoxia (N) or hypoxia (H) and treated with cycloheximide (CHX) for indicated time points
(B) or MG132 for 16 hr (C). The amounts of PML relative to that in untreated cells (B) and the fold of increase in PML level (C) are indicated.
(D) Hypoxia promotes PML ubiquitination independently of its sumoylation. LNCaP cells transfected with indicated constructs were cultured in normoxia or
hypoxia for 24 hr. Cells were harvested for immunoprecipitation and western blot analyses with indicated antibodies.
(E) HIF-1amediates hypoxia-induced PML down-regulation and KLHL20 up-regulation. PC3 cells infected with lentivirus carrying control or HIF-1a siRNA were
cultured in normoxia or hypoxia for 24 hr and were assayed for western blot with indicated antibodies.
(F) Schematic representations of the regulatory region of KLHL20 gene, the luciferase reporter constructs, and the ChIP primers used in this study. The positions
of HREs and the sequences of wild-type and mutant HREs are indicated.
(G) Promoter activity assay using PC3 cells transfected with indicated reporter construct and HIF-1a and cultured in normoxia or hypoxia for 6 hr.
(H) qChIP assay of PC3 cells cultured in normoxia or hypoxia for 6 hr. Results in (G) and (H) are presented as mean ± SD (**p < 0.005, ***p < 0.0005, n = 3).
See also Figure S1.
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Cul3-KLHL20 Targets PML to Feedback Control HIF-1of the KLHL20 gene, respectively (Figure 1F). Mutation of either
HRE reduced, and that of both HREs abolished, the hypoxia- or
HIF-1a-induced KLHL20 promoter activity (Figure 1G). Chro-
matin immunoprecipitation (ChIP) analysis confirmed the direct
binding of HIF-1a to these KLHL20-regulating regions, and
such binding was abrogated in cells expressing HIF-1a siRNAs
(Figure 1H; Figure S1H). Furthermore, by mining through public
gene expression databases, we revealed the coordinated up-
regulation ofKLHL20 and a number of HIF-1 and/or HIF-2 targets
in a cohort of colon cancer specimens, as compared with normal
colon tissues (Figure S1I). Together, our results indicate that
HIF-1 directly regulates KLHL20 transcription and that KLHL20
induction correlates with PML destabilization in response to
hypoxia.
Cul3-KLHL20 Ubiquitin Ligase Is Responsible for PML
Ubiquitination
The opposite regulations of KLHL20 and PML suggest that PML
is a substrate of the KLHL20-Cul3 ligase. As reported previously
(Lee et al., 2010), KLHL20 was partially localized in PML-NBs in
normoxia. During hypoxia, the KLHL20 immunofluorescent
intensities in NBs and nucleus were both elevated (Figure S2A),
correlating with the increase of total KLHL20 level. Cul3 was
more concentrated in the nucleus than in the cytoplasm, espe-
cially under hypoxia conditions (Figure S2B). These subcellular
distributions support the action of KLHL20-Cul3 complex on
PML. In line with this notion, we detected the endogenous inter-
action between PML and KLHL20 (Figure 2A). More importantly,
knockdown of KLHL20 by two different siRNAs abrogated
hypoxia-induced PML down-regulation, whereas knockdown
of RNF4 to a similar extent only slightly increased PML level in
hypoxic cells (Figure 2B). This KLHL20 siRNA-induced PML
accumulation in hypoxic cells was correlated with an increase
of PML-NBs (Figure 2C). Notably, KLHL20 depletion alsomoder-
ately up-regulated PML in normoxic cells (Figure 2B), consistent
with a low but detectable amount of KLHL20 in such conditions.
In keeping with these findings, PML-I ubiquitination was down-
regulated drastically in hypoxic andmoderately in normoxic cells
by KLHL20 siRNA (Figure 2D). Conversely, PML-I ubiquitination
was moderately increased by KLHL20 overexpression and dras-
tically elevated by coexpression of KLHL20 and Cul3 (Figure 2E).
KLHL20m6, which is defective in Cul3 binding (Lee et al., 2010),
failed to induce PML-I ubiquitination. The kelch domain deletion
mutant KLHL206K also could not confer PML-I ubiquitination
(Figure S2C), consistent with a role of this domain in substrate
recruitment (Pintard et al., 2004). However, the PML-I 3KR was
ubiquitinated at a level similar to wild-type protein by Cul3-
KLHL20, indicating that sumoylation is dispensable for this ubiq-
uitination event. Cul3-KLHL20 also promoted the ubiquitination
of another PML isoform, PML-IV (Figure S2D). Furthermore,
overexpression of KLHL20, but not KLHL20m6, promoted the
turnover of PML-I and PML-IV (Figures S2E and S2F) and
reduced the abundance of most, if not all, PML isoforms through
a proteasome-dependent manner (Figure S2G). These data indi-
cate a critical role of Cul3-KLHL20 complex in promoting the
ubiquitination of most PML isoforms and in mediating hypoxia-
induced PML down-regulation.
In contrast to the drastic down-regulation of PML protein, the
number and size of PML-NBs were only modestly reduced inresponse to hypoxia (Figures S2H and S2I). Because PML su-
moylation and interaction with SUMO-conjugated proteins are
essential for NB assembly (Lin et al., 2006), we investigated
these aspects in hypoxic cells. Remarkably, hypoxia induced
PML SUMO-1 conjugation (Figure S2J, left), which likely results
from reactive oxygen species–stimulated PML oligomerization/
sumoylation (Jeanne et al., 2010) and a global up-regulation of
protein SUMO-1 conjugation (Figure S2J, right). These phe-
nomena were accompanied by an increased interaction of
PML with Daxx, a PML partner in NBs. These data support
a role of hypoxia in stimulating PML-NB assembly through
a SUMO-dependent recruitment of NB-residing proteins, which
is expected to alleviate the negative regulation of PML-NBs
caused by hypoxia-induced PML degradation.
To address a direct role of Cul3-KLHL20 in PML ubiquitination,
in vitro ubiquitination assay was performed. Incubation of puri-
fied PML-I with the KLHL20-Cul3-Roc1 complex in the in vitro
ubiquitination reaction resulted in PML-I polyubiquitination.
Omission of the E1, E2, or E3 ligase complex and replacement
of Cul3 with a Roc1 binding-defective mutant (Cul36C) or
replacement of KLHL20with KLHL20m6abolishedPML-I ubiqui-
tination (Figure 2F). Furthermore, treatment of purifiedPML-I with
calf intestine phosphatase (CIP) abrogated PML-I ubiquitination
by KLHL20-Cul3-Roc1 complex. These data indicate that PML
is a direct substrate of Cul3-KLHL20 ubiquitin ligase. However,
targeting PML to this ligase requires a phosphorylation event.
CDK1 and CDK2 Phosphorylate PML S518 to Promote
KLHL20-Mediated PML Destruction
To identify the kinase responsible for targeting PML to KLHL20,
we screened a panel of kinase inhibitors. For simplicity, KLHL20
overexpression was used to mimic the effect of hypoxia. Among
these inhibitors, only the pan-CDK inhibitor roscovitine blocked
KLHL20-induced degradation of PML-I, whereas a CDK4/6-
specific inhibitor failed to do so (Figure S3A). Roscovitine also
blocked KLHL20-induced degradation of endogenous PML (Fig-
ure 3A) and Cul3-KLHL20-induced PML-I ubiquitination (Fig-
ure S3B). Furthermore, dominant negative (DN) mutant of
CDK1 or CDK2, but not CDK4 or CDK6, abrogated KLHL20-
induced PML-I degradation (Figure 3B). Consistent with these
findings, in serum-starved, G1-arrested cells, which should be
devoid of CDK1/2 activities, PML protein was up-regulated
because of a resistance to KLHL20-mediated degradation (Fig-
ures S3C and S3D). We next determined whether PML is
a substrate of CDK1/2. Purified Flag-PML-I was efficiently phos-
phorylated by CDK2-cyclin E or CDK1-cyclin B complex in vitro
(Figure 3C). Further analysis using various PML mutants demon-
strated S518 as the prime residue targeted by CDK2-cyclin E
and CDK1-cylcin B (Figure 3C; Figures S3E and S3F). However,
CDK6-cyclin D only modestly phosphorylated PML in vitro
(Figure 3C), which may account for its inability to promote
KLHL20-mediated PML degradation in vivo. To assess PML
S518 phosphorylation in vivo, we generated an antibody that
recognizes S518-phosphorylated PML. This antibody reacted
with WT PML-I and PML-I S527A, but not with PML-I S518A
(Figure S3G). With this antibody, we showed that roscovitine
compromised S518 phosphorylation of endogenous PML in
multiple cell lines (Figure S3H). Furthermore, DNmutant of CDK1
or CDK2 blocked, whereas overexpression of CDK1-cyclin BCancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc. 217
Figure 2. KLHL20 Mediates PML Ubiquitination and Destruction in Hypoxic and Normoxic Cells
(A) KLHL20 interacts with PML in PC3 cells treated with hypoxia and MG132 for 24 hr.
(B) Western blot analysis of PML level in LNCaP or PC3 cells stably expressing indicated siRNA and cultured under normoxia or hypoxia for 24 hr. The knockdown
efficiency of individual siRNA in each cell line was determined by RT/qPCR and is presented as percentage of decrease in mRNA level (bottom).
(C) KLHL20 down-regulates PML-NBs in hypoxic cells. Cells as in (B) were cultured in hypoxia for 24 hr, stained with PML antibody and DAPI, and examined by
confocal microscopy. The representative immunofluorescent image (left) and the average PML-NB numbers per cell calculated from 60 cells in each population
(right) are presented. Scale bar, 20 mm.
(D and E) KLHL20 promotes PML ubiquitination in vivo. LNCaP cells stably expressing various siRNAs (D) or HeLa cells transfected with indicated constructs
(E) were examined for PML ubiquitination as in Figure 1D.
(F) In vitro ubiquitination of PML by KLHL20-Cul3-Roc1 complex. Flag-PML-I purified from baculovirus and pretreated with or without CIP was subject to in vitro
ubiquitination reaction in the presence of E1, E2, E3 complex and/or ubiquitin (see Experimental Procedures), and examined by western blot with anti-Flag
antibody. Results in (B) and (C) are presented as mean ± SD (***p < 0.0005, n = 3).
See also Figure S2.
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ure 3D). These results indicate a direct and physiological role
of CDK1/2 in phosphorylating PML at S518, which in turn
promotes PML ubiquitination by the Cul3-KLHL20 ligase.
The identification of an essential role of CDK1/2 in KLHL20-
mediated PML ubiquitination raised a concern as to whether218 Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc.the same kinases mediate PML ubiquitination in hypoxia condi-
tions, given that prolonged hypoxia treatment of certain cells
results in cell cycle arrest. We thus evaluated the influence of
hypoxia on CDK1/2 activities. Of note, PML down-regulation
was observed as early as 8 hr of hypoxia treatment, and only
a trace amount of PML was detected at 24 hr of treatment
Figure 3. CDK1 and CDK2 Phosphorylate PML in Both Normoxia and Hypoxia to Promote KLHL20-Induced PML Destruction
(A) Western blot analysis of endogenous PML in 293T cells transfected with KLHL20 and/or treated with roscovitine. The relative levels of PML are indicated.
(B) DN mutant of CDK1 or CDK2 blocks KLHL20-induced PML-I degradation in 293T cells.
(C) Purified PML-I and its mutant were phosphorylated by indicated CDK-cyclin complexes in vitro and were analyzed by autoradiography (top). Equal inputs of
various substrates were assessed by Coomassie blue staining (bottom).
(D) Western blot analysis of PML S518 phosphorylation in 293T cells overexpressing indicated CDK DN mutant (left) or CDK-cyclin complex (right).
(E) Kinase activities of CDK1 and CDK2 immunoprecipitated from PC3 cells cultured in normoxia or hypoxia for 24 hr were assayed by in vitro phosphorylation of
histone H1. The input of CDK1/2 is shown on the bottom.
(F) Western blot analysis of PML S518 phosphorylation in PC3 cells cultured as in (E).
(G and H) Western blot analysis of S518-phosphorylated PML (G) and total PML (H) in PC3 cells cultured as in (E) and treated with indicated inhibitors for 24 hr.
To ensure an accurate comparison, different amounts of lysate from hypoxic cells were loaded in (F) and (G).
See also Figure S3.
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ure 3E) as well as the PML S518 phosphorylation level (Figure 3F)
were not decreased by 24 hr treatment of hypoxia. Furthermore,
no significant difference in the cell cycle profiles of multiple
cancer cell lines was observed at this time point, even though
an enrichment of G1 population was detected 1 day later (Fig-
ure S3I). These observations suggest the capability of CDK1/2
in phosphorylating PML during the period of hypoxia when
KLHL20 is highly induced to promote PML ubiquitination. In
keeping with this notion, roscovitine or a CDK1/2-specific inhib-
itor diminished PML S518 phosphorylation (Figure 3G) and
degradation (Figure 3H) in hypoxia. Thus, CDK1/2 is involved in
PML destruction in both normoxia and hypoxia conditions.
In contrast to the normoxia and hypoxia conditions, the activi-
ties of CDK1/2 and PML S518 phosphorylation were severely
compromised in an ischemia-mimetic cell culture system
(Figures S3J and S3K). In line with the requirement of CDK1/2 in
KLHL20-mediated PML degradation, PML protein was accumu-
lated under this condition (Figure S3K, bottom), which is consis-
tent with a previous study performed in amuscle ischemiamodel
(Bernardi et al., 2006). These findings suggest a biphasic regula-
tion of PML stability with the drop of oxygen concentrations.
S518 Phosphorylation and Pin1-Mediated
Prolylisomerization Promote the Recruitment
of PML to KLHL20
To further understand the influence of CDK1/2-mediated phos-
phorylation on PML ubiquitination by Cul3-KLHL20, we used
the phosphorylation-defective mutant PML-I S518A. Unlike the
wild-type protein, this mutant could no longer interact with
KLHL20 both in vivo (Figure 4A) and in vitro (Figure S4A) and
was defective in KLHL20-induced ubiquitination (Figure 4B)
and degradation (Figure S4B). More importantly, the S518A
mutant was turned over more slowly than wild-type protein in
hypoxia, and this difference in turnover rate was abrogated by
KLHL20 depletion (Figure 4C). These results support a notion
that S518 phosphorylation facilitates the recruitment of PML to
Cul3-KLHL20 for ubiquitination and, subsequently, degradation.
A previous study revealed that PML phosphorylated at four
pS-P motifs, including the pS518-P519 motif, promotes its
degradation mediated by Pin1 (Reineke et al., 2008). We found
that S518 mutation blocked PML interaction with Pin1 both
in vivo (Figure 4D) and in vitro (Figure S4C). In viewing of the
prime role of pS518-P519 motif in Pin1 binding, we thought to
test a model whereby Pin1-mediated isomerization on CDK-
phosphorylated PML potentiates the recruitment of PML to
Cul3-KLHL20 for ubiquitination. In keeping with this model,
although CDK1-mediated phosphorylation enhanced PML
ubiquitination by KLHL20-Cul3-Roc1 in vitro, incubation of
CDK-phosphorylated PML with Pin1, but not its substrate
binding–defective mutant Pin1 W34A, further augmented this
ubiquitination (Figure S4D). Consistent with this in vitro finding,
Pin1 silencing abolished PML-I interaction with KLHL20 (Fig-
ure S4E) and ubiquitination by KLHL20-Cul3 in vivo (Figure 4E).
Consequently, KLHL20-induced down-regulations of PML-I
(Figure S4F) and endogenous PML (Figure S4E, bottom) were
blocked. Pin1 depletion also abrogated hypoxia-induced PML
destruction (Figure 4F). Collectively, our study uncovers a PML
degradation pathway, in which sequential modifications of220 Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc.PML by CDK1/2 and Pin1 at the S518-P519 motif facilitate the
recruitment of PML to Cul3-KLHL20 for ubiquitination. Under
hypoxia conditions, the drastic up-regulation of KLHL20 leads
to a robust PML ubiquitination through this pathway, thereby
greatly reducing PML abundance. Notably, the S518 and P519
residues are present in PML isoforms I to VI (Bernardi and Pan-
dolfi, 2007) and are evolutionarily conserved (Figure S3L), thus
highlighting the importance and prevalence of this pathway in
regulating PML abundance.
KLHL20-Mediated PML Destruction Amplifies Tumor
Hypoxia Responses
A previous report indicates that PML is itself a negative regulator
of HIF-1a protein synthesis through a repression of mTOR
activity (Bernardi et al., 2006). Accordingly, knockdown of PML
in PC3 cells enhanced hypoxia-induced HIF-1a (Figure S5A).
Thus, the HIF-1a-induced, KLHL20-mediated PML destruction
pathway may function to derepress mTOR and HIF-1a, thereby
participating in a double-negative feedback loop to amplify
HIF-1a signaling. In line with this notion, depletion of KLHL20
in PC3 cells led to an enhanced decline of mTOR activity (moni-
tored by the phosphorylation of mTOR downstream molecules
S6 kinase and S6) and a decreased induction of HIF-1a in
response to hypoxia treatment (Figure 5A). More importantly,
depletion of PML in the KLHL20-knockdown cells completely
rescued mTOR activity and HIF-1a induction (Figure 5A), indi-
cating the involvement of PML in KLHL20 siRNA-induced
mTOR and HIF-1a down-regulation. The KLHL20-PML pathway
also led to an increased HIF-2a induction under more stringent
hypoxia conditions (Figure S5B). Conceivably, KLHL20-depleted
cells exhibited a lower induction of HIF targetsVEGF (Figure S5C)
and GLUT1 (Figure 5B) than did control siRNA-expressing cells,
and depletion of both KLHL20 and PML reversed these effects.
Thus, the KLHL20-PML pathway is critical for hypoxic cells to
achieve a full induction of HIF signaling.
Next, we tested whether the influence of KLHL20-PML path-
way on HIF induction could potentiate tumor hypoxia responses.
Hypoxia treatment of control siRNA-expressing PC3 cells re-
sulted in a decrease of apoptosis induced by doxorubicin, and
this effect was enhanced by PML knockdown (Figure 5C). Impor-
tantly, the chemoresistance effect of hypoxia was abrogated
by KLHL20 silencing and was rescued by KLHL20 and PML
double knockdown (Figure 5D). Similar to many other tumor
cells, hypoxia treatment of control siRNA-expressing PC3 cells
induced epithelial-mesenchymal transition (EMT), as evidenced
by morphological changes, down-regulation of E-cadherin, and
up-regulation of N-cadherin and vimentin (Figure 5E), and pro-
moted migration (Figure 5F, bottom). Remarkably, these effects
were all attenuated by KLHL20 silencing and rescued by double
knockdown of KLHL20 and PML. PML knockdown alonemoder-
ately enhanced hypoxia-induced cell migration (Figure 5F, top),
in line with the elevation of HIF-1a under such conditions. Collec-
tively, our findings indicate that the KLHL20-PML pathway is part
of a feedback control mechanism to amplify HIF-1-mediated
tumor hypoxia responses.
If KLHL20-PML pathway indeed participates in the HIF-1 feed-
back regulation, overexpression of a nondegradable mutant
PML S518A should disrupt this feedback loop. We thus stably
expressed this mutant in PC3 cells. For comparison, wild-type
Figure 4. S518 Phosphorylation Mediates Pin1-Dependent Prolylisomerization to Promote PML Targeting to KLHL20
(A) PML-I, but not PML-I S518A, coimmunoprecipitated endogenous KLHL20 from 293T transfectants.
(B) S518 mutation impairs KLHL20-dependent PML ubiquitination. 293T cells transfected with indicated constructs were assayed for PML-I ubiquitination.
(C) Western blot analysis of the turnover rate of PML-I and its mutant in hypoxic LNCaP cells expressing indicated siRNA and treated with CHX.
(D) 293T cells expressing Flag-PML-I or its mutant were treated with or without roscovitine, and then were analyzed for PML/Pin1 interaction by immunopre-
cipitation.
(E) Pin1 promotes KLHL20-dependent PML ubiquitination. 293T cells expressing control or Pin1 siRNAwere transfected with indicated constructs and then were
assayed for PML-I ubiquitination.
(F) Pin1 mediates hypoxia-induced PML destruction. PC3 cells stably expressing indicated siRNAs were cultured in normoxia or hypoxia and were analyzed by
western blot.
See also Figure S4.
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Cul3-KLHL20 Targets PML to Feedback Control HIF-1PML was also introduced. As expected, PML S518A was accu-
mulated to a higher level than wild-type protein, despite their
comparable mRNA levels (Figure 6A). Remarkably, PML S518A
overexpression abrogated HIF-1a induction and hypoxia-
induced GLUT1 expression, chemoresistance, and migration
(Figures 6B–6E). These hypoxia responses, however, were still
observed in cells expressing wild-type PML, albeit reaching to
lower extents in comparison with the parental PC3 cells. Thesefindings further support the impact KLHL20-mediated PML
degradation on amplifying HIF-1 signaling.
KLHL20-Mediated PML Destruction Elicits Tumor-
Promoting Functions Under Normoxia Conditions
Because KLHL20 potentiates PML degradation not only in
hypoxic cells but also in normoxic cells, we surmised that the
KLHL20-PMLpathwaymaycontribute tocertain tumor-promotingCancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc. 221
Figure 5. KLHL20-Mediated PML Destruction Amplifies HIF-1 Signaling
(A and B) Western blot analysis of phospho-S6 kinase (pS6K), S6 kinase, phospho-S6 (pS6), S6, and HIF-1a (A), and RT-qPCR analysis ofGLUT1 (B) in PC3 cells
stably expressing indicated siRNAs and treated with hypoxia for various time points. The relative amounts of pS6K and pS6, normalized to their total levels, are
indicated. The expression levels of KLHL20 and PML in these stable lines are shown in Figure S6A (lanes 1, 5, 6, and 7).
(C and D) Apoptosis assays of PC3 cells expressing indicated siRNAs and treated with or without doxorubicin in hypoxia or normoxia.
(E) EMT assays for cells as in (A) cultured in normoxia or hypoxia for 24 hr. The cell morphology was visualized by phase-contrast microscopy (top), whereas the
expression of E-cadherin, N-cadherin, and vimentin was determined by western blot (bottom). Scale bar, 20 mm.
(F) PC3 cells expressing indicated siRNAs were assayed for migration under normoxia or hypoxia for 12 hr (top) or 16 hr (bottom). Data in (B), (C), (D), and (F) are
presented as mean ± SD (*p < 0.05, **p < 0.005, ***p < 0.0005, n = 3).
See also Figure S5.
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Cul3-KLHL20 Targets PML to Feedback Control HIF-1functions in normoxia. Indeed, depletion of KLHL20 in PC3 cells
led to a reduction in forming soft-agar colonies, and this effect
was rescued by double depletion of KLHL20 and PML (Fig-
ureS5D).KLHL20silencing innormoxiaalsodecreasedcellmigra-222 Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc.tion (Figure 5F, bottom, gray brackets) and modestly promoted
doxorubicin-induced apoptosis (Figure 5D, gray brackets), and
all these effects were rescued by combined depletion of KLHL20
and PML. Consistent with a previous report (Reineke et al.,
Figure 7. KLHL20-Mediated PML Destruction Promotes Tumor
Angiogenesis and Growth
(A) Tumor growth of PC3 cells expressing indicated siRNA in a xenograft
model.
(B and C) Quantitative data of CD31 (B) and Ki-67 (C) staining of comparable-
sized tumors derived from indicated cells. Data are presented as mean ± SD
(**p < 0.005, ***p < 0.0005, n = 3).
(D) Western blot analysis of the expression of PML, KLHL20, and HIF-1a in
tumors derived from indicated cells.
See also Figure S6.
Figure 6. PML S518A Blocks HIF-1a Induction and Tumor Hypoxia
Responses
(A) PC3 cells transduced with indicated lentivirus were analyzed for total PML
mRNA expression and PML-IV protein expression by RT/PCR and western
blot, respectively.
(B and C) Cells as in (A) were exposed to hypoxia for 0 or 8 hr and then were
assayed for HIF-1a expression by western blot and for GLUT1 expression by
RT-PCR.
(D) Apoptosis assay of cells as in (A) treated with or without doxorubicin under
normoxia or hypoxia.
(E) Cells as in (A) were assayed for migration in normoxia or hypoxia for 16 hr.
Data in (A), (C), (D), and (E) are presented as mean ± SD (*p < 0.05, **p < 0.005,
***p < 0.0005, n = 3).
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Cul3-KLHL20 Targets PML to Feedback Control HIF-12010), PML depletion alone promoted migration in normoxia
(Figure 5F, top, gray bracket). Conversely, overexpression of
KLHL20-resistant PML S518A markedly potentiated apoptosis
and inhibited migration in normoxia, whereas wild-type PML
elicited weaker effects (Figures 6D and 6E, gray brackets). These
findings support the contribution of KLHL20-PML pathway to
tumor promotion in normoxia, even though the effect is less prom-
inent than that observed in hypoxia.
KLHL20-Mediated PML Destruction Promotes Tumor
Angiogenesis and Growth In Vivo
Next, we evaluated the influence of KLHL20-PML pathway on
tumor growth and angiogenesis using xenograft models. To
specifically assess angiogenesis, we generated tumor cell lines
with comparable proliferation and transformation potencies.
This was achieved by infecting PC3 cells with a low titer of lenti-
virus carrying KLHL20 siRNA. The transduced cells (KLHL20
siRNA #1L and KLHL20 siRNA #2L) as well as the KLHL20/
PML double-depleted cells displayed lower KLHL20 knockdown
efficiencies than aforementioned PC3 derivatives (Figure S6A).
We confirmed that this new set of cell lines exhibited similarrate of proliferation in vitro and similar efficacy to form colonies
in soft agar (Figures S6B and S6C). However, when they were in-
jected into nude mice, their potency to form tumor was signifi-
cantly different (Figure 7A). Tumors derived from KLHL20-
depleted cells were smaller than those from parental PC3 cells
or from cells depleted both KLHL20 and PML. Immunohisto-
chemistry (IHC) analyses using tumors with a comparable size
(180 mm3) revealed that tumors derived from KLHL20-
depleted cells had significant lower microvessel density and
proliferation rate than those from cells expressing control siRNA
or both PML and KLHL20 siRNAs, as determined by CD31 and
Ki67 staining, respectively (Figures 7B and 7C; Figures S6D
and S6E). The KLHL20-depleted tumors also exhibited higher
PML and lower HIF-1a levels than similar-sized tumors from
other two groups (Figure 7D; Figure S6F). Consistent with a
previous report (Bernardi et al., 2006), PML depletion alone did
not significantly altered soft-agar colony formation of PC3 cells,Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc. 223
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Cul3-KLHL20 Targets PML to Feedback Control HIF-1but enhanced tumor growth, angiogenesis, and HIF-1a induction
in xenograft model (Figures S6G–S6I). Thus, the KLHL20-
induced PML destruction pathway promotes tumor angiogen-
esis and tumor growth in vivo, and these functions are mediated
at least in part through the elevation of HIF-1 signaling.
HIF-1a/KLHL20/Pin1/PML Pathway Is Manifested
in Human Prostate Cancer and Is Up-Regulated
in High-Grade Tumors
To validate the clinical relevance of KLHL20-mediated PML
destruction pathway to human cancer and its contribution to
PML down-regulation in tumors, we analyzed the expression
profiles of HIF-1a, Pin1, KLHL20, and PML in consecutive slides
from 79 human prostate cancer patients and 17 benign prostate
hyperplasia (BPH) cases. Remarkably, IHC analysis revealed
drastic differences in the expression levels of these four proteins
between tumor and BPH, and representative images are shown
in Figures S7A and S7B. Compared to BPH, tumor specimens
exhibited significant up-regulations of HIF-1a, KLHL20, and
Pin1 and down-regulation of PML (Figure 8A). In addition, we
found that PML expression was inversely correlated with Pin1,
KLHL20, and HIF-1a expression, whereas a positive correlation
was observed between the expression of HIF-1a and KLHL20
(Figure 8B). These findings support the existence of HIF-1a/
KLHL20/Pin1/PML pathway in human prostate cancer. More
importantly, the percentage of patients displaying the signature
of high HIF-1a, high KLHL20, high Pin1, and low PML expression
pattern, which suggests a hyperactive feature of the PML de-
struction pathway, was progressively increased with the in-
crease of tumor grade, and a significant difference was observed
between each of the three groups: prostatic intraepithelial
neoplasia (PIN), Gleason score 6/7, and Gleason scoreR 8 (Fig-
ure 8C). These findings suggest a relevance of the HIF-1a/Pin1/
KLHL20/PML signaling axis to tumor progression.
DISCUSSION
Our study reveals a central role of the Cul3 substrate adaptor
KLHL20 in the regulation of hypoxia responses and tumor
progression (Figure 8D, top). KLHL20 is transcriptionally up-
regulated by HIF-1 andmediates hypoxia-induced PML polyubi-
quitination. However, efficient recruitment of PML to KLHL20
requires two consecutive posttranslational modifications at
PML S518-P519, phosphorylation by CDK1/2, and prolyl
cis/trans isomerization by Pin1. Importantly, this HIF-1-induced,
KLHL20-mediated PML destruction, together with the PML-
induced, mTOR-mediated HIF-1a repression (Bernardi et al.,
2006), constitutes a double-negative feedback loop to amplify
HIF-1 signaling. The pathophysiological significance of this
HIF-1a feedback control is evidenced by the finding that
KLHL20 silencing compromises multiple tumor hypoxia re-
sponses, which are all rescued by double depletion of KLHL20
and PML. Furthermore, ectopic expression of KLHL20-resistant
PML S518A similarly abrogates tumor hypoxia responses.
Besides amplifying HIF-1 signaling, KLHL20 also potentiates
PML degradation. Because these two events elicit partially over-
lapping biological functions, such as promoting migration and
survival, they could act in synergism to contribute to tumor
progression in hypoxia. The clinical relevance of our findings is224 Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc.supported by the observations that PML down-regulation corre-
lates with HIF-1a, Pin1, and KLHL20 up-regulation in human
prostate cancer and that hyperactivation of this pathway corre-
lates with high-grade tumors. Given that overexpression of
HIF-1a is widespread in human cancers through hypoxic or non-
hypoxic mechanism (Henze and Acker, 2010), the impact of
HIF-1-KLHL20-PML pathway may extend beyond the prostate
cancer, and thus our study may provide molecular insights into
PML down-regulation in diverse cancer types (Gurrieri et al.,
2004).
It is worth noting that HIF-1a is induced transiently under
hypoxia conditions, and several negative feedback regulatory
mechanisms are responsible for its down-regulation during
prolonged hypoxia (Henze and Acker, 2010). This raises the
question why the positive feedback regulation of HIF-1a, as
described in this study, evolved and how this regulation could
be beneficial for tumor progression. Because tumor cells are
often subject to microenvironments with fluctuating oxygen
concentrations (Henze and Acker, 2010), the positive feedback
regulation of HIF-1a allows a rapid and robust induction of
hypoxia responses, which could be exploited by tumor to ensure
a timely adjustment during acute hypoxia conditions, thereby
maintaining cell homeostasis and survival. However, in response
to chronic hypoxia, the KLHL20-mediated HIF-1a feedback
control may be dampened because of the decrease of CDK1/2
activities, as deduced by an enrichment of G1-arrested cells
(Figure S3I). This adjustment, together with the activation of
various negative feedback mechanisms, would lead to an ulti-
mate decline of HIF-1a level, thus allowing tumor cells to reset
their threshold for HIF-1a induction in response to the next run
of hypoxia stimulation.
Although this study reveals the participation of KLHL20-
mediated PML degradation in HIF-1 feedback regulation, we
do not exclude the involvement of other NB-residing proteins
in KLHL20-regulated HIF-1 signaling. Furthermore, it is possible
that a proteasome-independent mechanism also contributes to
PML down-regulation during hypoxia. In addition, despite the
down-regulation of PML in tumor cells, tumor-associated endo-
thelial cells and infiltrating lymphocytes often exhibit large
number of PML-NBs (Gurrieri et al., 2004), implying the existence
of cell type–specific regulation of PML. Alternatively, this differ-
encemay occur at the level of PML-NB assembly, because regu-
lation of PML protein and PML-NB assembly can be uncoupled
in certain circumstances, including hypoxia conditions.
Previous studies indicated that phosphorylation at S565 by
CK2 (Scaglioni et al., 2006) and sumoylation at K160 (Lalle-
mand-Breitenbach et al., 2001) promote PML ubiquitination.
Although the ubiquitin ligase RNF4 acts selectively on K160-su-
moylated PML (Lallemand-Breitenbach et al., 2008), KLHL20-
based E3 ligase can efficiently catalyze unsumoylated PML.
Furthermore, S565 phosphorylation is likely dispensable for tar-
geting PML to KLHL20, becauseCK2 inactivation does not affect
PML degradation by KLHL20 (Figure S3A). Nevertheless, we
show that ubiquitination catalyzed by KLHL20-associated E3
ligase requires phosphorylation and prolylisomerization on the
S518-P519 motif of PML. Because this motif is evolutionally
conserved and present in most PML isoforms, the KLHL20-
PML pathway likely represents a general mechanism for modu-
lating PML stability under hypoxia conditions. Notably, this motif
Figure 8. The HIF-1a/KLHL20/Pin1/PML Pathway Is Manifested in Human Prostate Cancer and Associated with High-Grade Tumor
(A) Summary of the HIF-1a, KLHL20, Pin1, and PML expression profiles.
(B) Positive correlation of KLHL20 and HIF-1a expression and inverse correlations of HIF-1a and PML expression, KLHL20 and PML expression, as well as Pin1
and PML expression in all 96 prostate specimens.
(C) Percentage of patients displaying the signature expression pattern of high HIF-1a, high KLHL20, high Pin1, and low PML in PIN, Gleason score (GS) 6 or 7,
and GSR 8. Total case number in each group is indicated on the bottom and patients without grade information were excluded. Fisher’s exact test was used for
comparison between groups.
(D) Model for KLHL20-mediated PML degradation in tumor development and progression under hypoxia and normoxia conditions.
See also Figure S7.
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Cul3-KLHL20 Targets PML to Feedback Control HIF-1is also present in the oncogenic PML-RARa protein. Recent
studies indicated a role of hypoxia and hypoxia-mimetic agent
in stimulating the differentiation of acute myeloid leukemic cells(Huang et al., 2003; Liu et al., 2006), so it would be important
to determine whether this effect is mediated by the degradation
of PML-RARa through a KLHL20-dependent mechanism.Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc. 225
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Cul3-KLHL20 Targets PML to Feedback Control HIF-1Although the KLHL20-dependent mechanism is responsible
for hypoxia-induced PML destruction, we demonstrate that the
same pathway also acts on normoxic cells to confer tumor-
promoting functions, such as transformation, migration, and
survival, albeit with a lower efficacy (Figure 8D, bottom). The
requirement of CDK1/2 activities for targeting PML to KLHL20
in normoxia suggests the existence of a cell cycle–dependent
regulation of PML. Accordingly, PML protein level is highest in
G1, drops progressively in S and G2 (Dellaire et al., 2006), and
is elevated in G1-arrested cells (Figures S3C and S3D). Future
study will determine the impact of KLHL20-mediated PML
degradation on cell cycle progression.
In summary, our study identifies a pathway by which KLHL20-
mediated PML destruction controls the robust induction of
HIF-1a. Although HIF-1a induction and PML destruction could
act coordinately and/or synergistically to promote tumor pro-
gression in hypoxia, the latter also contributes to tumor promo-
tion in normoxia. Thus, this pathway not only provides molecular
insights into aberrant PML down-regulation in human cancers
but also plays a crucial and versatile role in tumor development.
Blockage of this pathway may potentially be a therapeutic




Plasmids encoding Flag-KLHL20, Myc-KLHL20, Myc-KLHL20m6, Myc-ubiq-
uitin, Myc-hCul3, Myc-Roc1, and Cul36C were described previously (Lee
et al., 2010). To clone KLHL20 promoter, a DNA fragment corresponding to
nucleotides 397 to +1102 of the KLHL20 gene (numbered relative to the
transcription initiation site) was amplified from the genomic DNA of 293 cells
and inserted into the pGL3-Basic vector. Construct for HA-PML-IV was
described elsewhere (Lin et al., 2006), whereas Flag-PML-I was a gift from
Ming-Zong Lai. Constructs expressing Pin1 and its mutants were described
elsewhere (Lu et al., 1996; Zhou et al., 2000). The full-length cDNAs for
CDK1, CDK2, CDK4, and CDK6 were amplified by RT-PCR using total
RNAs from HeLa cells and then subcloned to pRK5F or pRK5M vector.
PML mutants, CDK mutants (CDK1 D146N, CDK2 D145N, CDK4 D158N,
and CDK6 D163N), and KLHL20 promoter mutants were generated by site-
directed mutagenesis. HIF-1a and HIF-1a(6ODD) were provided by Kou-
Juey Wu. To generate lentiviral and baculoviral expression constructs,
PML-IV and PML-I were amplified by PCR and cloned to pLenti6-GW-V5
and pVL1392 vectors, respectively.
In Vitro and In Vivo Ubiquitination
For in vitro ubiquitination, 300 ng of baculovirally purified Flag-PML-I was
treated with 0.75 unit of CIP or phosphorylated by CDK1-cyclin B (see
Supplemental Experimental Procedures), and/or incubated with 200 ng of
GST-Pin1 (or its mutant) at 4C for 1 hr. Roc1-Cul3-KLHL20 complex was puri-
fied using Glutathione-Sepharose beads from lysates of 293T cells transfected
with GST-Cul3, Myc-KLHL20, and Myc-Roc1. The purified complex bound on
beads was incubated at 37C for 4 hr in 20 ml reaction mixture containing
50 mM Tris (pH 7.5), 1 mM ubiquitin aldehyde, 20 mM MG132, 5 mM MgCl2,
2 mM ATP, 2 mMNaF, 1 mMDTT, 10 mg ubiquitin, 10 mM creatine phosphate,
500 ng creatine kinase, 40 ng yeast E1 enzyme, 500 ng E2 enzyme (UbcH5a),
and 300 ng PML-I.
For analyzing in vivo ubiquitination of PML, cells were transfected with
various constructs together with myc-ubiquitin and Flag-PML-I or Flag-
PML-IV and treated with MG132 for 16 hr. Cells were lysed by RIPA lysis
buffer, and lysates were used for immunoprecipitation with anti-Flag antibody
followed by western blot with anti-myc antibody. Alternatively, cells were
transfected with various constructs together with His-ubiquitin and Flag-
PML-I and treated with MG132. Cells were lysed by buffer A (6 M guani-226 Cancer Cell 20, 214–228, August 16, 2011 ª2011 Elsevier Inc.dine-HCl, 0.1 M Na2HPO4/NaH2PO4 [pH 8.0], and 10 mM imidazole), and
lysates were incubated with Ni-NTA agarose for 3 hr at 4C. The beads
were washed once with buffer A, twice with buffer A/TI (1 vol buffer A: 3 vol
buffer TI [25 mM Tris-HCl, pH 6.8, and 20 mM imidazole]), and three times
with buffer TI, and then analyzed by western blot. In all experiments, equal
expression of myc-ubiquitin or His-ubiquitin was verified by western blot
analysis.
Apoptosis assay
Cells were cultured under normoxia or hypoxia conditions for 24 hr and then
treated with 2 mg/ml doxorubicin for 24 hr under normoxia or hypoxia.
Apoptotic cells were assayed by Annexin V-APC kit (BD PharMingen) and
analyzed by flow cytometry.
Cell Migration Assays
For Transwell migration assay, the underside of Transwell polycarbonate
membrane (8-mm pore size; Millipore) was coated with 30 ng/ml collagen I.
6 3 104 cells resuspended in serum-free medium containing 1% BSA were
plated onto the upper chamber, and the medium containing 1% BSA and
10% FCS was added to the lower chamber. Cells were incubated at 37C
under normoxia or hypoxia. At the end point of incubation, cells that had
migrated onto the lower membrane surface were fixed by 4% formaldehyde,
stained with DAPI, and counted.
Tissue Specimens and IHC Analysis
Human prostate specimens were obtained from National Taiwan University
Hospital Tissue Bank. All samples were deidentified prior to analysis. Studies
involving these tissues were approved by the Institutional Review Boards at
College of Medicine, National Taiwan University and Academia Sinica. For
IHC staining, paraffin sections of 5 mm thickness on coating slides were
heat-denatured with 10 mM sodium citrate buffer (pH 6.0) for 15 min for
antigen retrieval and then incubated with anti-HIF-1a antibody (Novus, 1:25
dilution), anti-KLHL20 antibody (1:400 dilution), anti-PML antibody (1:50 dilu-
tion), or anti-Pin1 antibody (1:100 dilution). All staining procedures were per-
formed using autostaining system (Ventana Medical System, Inc., Arizona)
with basic DAB detection kit according to the manufacturer’s protocol. The
couterstaining was performed with hematoxylin. The IHC staining was scored
as negative/weak positive (score 0), moderate positive (score 1+), and strong
positive (score 2+) according to percentage of cells staining positive and stain-
ing intensity, and only the nuclear signal of HIF-1awas considered. For HIF-1a,
Pin1, and KLHL20 staining, samples that showed strong positive (score 2+)
were defined as high expression. For PML staining, because 62.5% of the
specimens exhibited score 0, samples with score 1+ or 2+ were considered
as high expression. IHC analysis on xenograft tumors was described in
Supplemental Experimental Procedures.
Soft-Agar Colony-Formation Assay and Xenotransplantation
For assaying colony formation in soft agar, 2 3 104 PC3 derivatives were
resuspended in 0.3% top agar. Colony formed after 3 weeks were stained
by crystal violet and counted. For assaying tumor growth in xenograft model,
7-week-old BALB/c nude mice housed in specific pathogen-free conditions
were injected s.c. with 2.5 3 106 PC3 derivatives (n = 7 for each group)
mixed with PBS and Matrigel (vol/vol, 1:1). All mouse experiments were con-
ducted with approval from the Experimental Animal Committee, Academia
Sinica.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2011.07.008.
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